Survival benefit from maintenance therapy after first-line chemotherapy in advanced non-small cell lung cancer: A meta-analysis.

被引：0
|
作者：
Chouahnia, Kader
Guetz, Gaetan Des
Uzzan, Bernard
Nicolas, Patrick
Morere, Jean F.
机构：
[1] CHU Avicenne, Bobigny, France
[2] Dept Oncol, Bobigny, France
[3] Hop Avicenne, F-93009 Bobigny, France
[4] Hop Avicenne, Dept Oncol, F-93009 Bobigny, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18003
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Is There a Benefit to Maintenance Therapy After First Line Chemotherapy in Advanced Non-small Cell Lung Cancer - a Systematic Review With Meta-analysis
    Guetz, G. Des
    Uzzan, B.
    Chouahnia, K.
    Nicolas, P.
    Perol, M.
    Morere, J. F.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S593 - S593
  • [2] Maintenance therapy with gefitinib after first-line chemotherapy in patients affected by advanced non-small cell lung cancer
    Mencoboni, M.
    Bergaglio, M.
    Serra, M.
    Ivaldi, G. P.
    Tredici, S.
    Racchi, O.
    Rebella, L.
    Galbusera, V.
    Grosso, M.
    Faravelli, B.
    [J]. ANTICANCER RESEARCH, 2007, 27 (6C) : 4425 - 4429
  • [3] A Phase Ⅱ Trial of Gefitinib as Maintenance Therapy after First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in China
    Lu Yang 1
    1Department of Thoracic Medical Oncology
    [J]. Chinese Journal of Cancer Research, 2010, 22 (01) : 1 - 9
  • [4] Impact of gemcitabine (G) on the activity of first-line chemotherapy in non-small cell lung cancer (NSCLC): A meta-analysis.
    Pappagallo, G. L.
    Belvedere, O.
    Vinante, O.
    Grossi, F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 398S - 398S
  • [5] A phase II trial of gefitinib as maintenance therapy after first-line chemotherapy for advanced non-small cell lung cancer in China
    Yang, Lu
    Wang, Zhi-jie
    An, Tong-tong
    Bai, Hua
    Zhao, Jun
    Duan, Jian-chun
    Li, Ping-ping
    Wu, Mei-na
    Sun, Hong
    Liang, Li
    Wang, Jie
    [J]. CHINESE JOURNAL OF CANCER RESEARCH, 2010, 22 (01) : 1 - 9
  • [6] Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
    Coudert, B.
    Ciuleanu, T.
    Park, K.
    Wu, Y. -L.
    Giaccone, G.
    Brugger, W.
    Gopalakrishna, P.
    Cappuzzo, F.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (02) : 388 - 394
  • [7] Pharmacoeconomic analysis of consolidation therapy with pemetrexed after first-line chemotherapy for non-small cell lung cancer
    Tsuchiya, Takanori
    Fukuda, Takashi
    Furuiye, Masashi
    Kawabuchi, Koichi
    [J]. LUNG CANCER, 2011, 74 (03) : 521 - 528
  • [8] Immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for non-small cell lung cancer: A systematic review and meta-analysis.
    Abdelazeem, Basel
    Abbas, Kirellos Said
    Labieb, Fatma
    Arida, Abdul Karim
    El-Shahat, Nahla Ahmed
    Shehata, Joseph
    Kandah, Emad
    Malik, Bilal
    Akanbi, Maxwell Oluwole
    Rafae, Abdul
    Tahir, Nayha
    Wahab, Ahsan
    Ehsan, Hamid
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer
    Itaya, Toru
    Yamaoto, Nobuyuki
    Ando, Masahiko
    Ebisawa, Masako
    Nakamura, Yukiko
    Murakami, Haruyasu
    Asai, Gyo
    Endo, Masahiro
    Takahashi, Toshiaki
    [J]. CANCER SCIENCE, 2007, 98 (02) : 226 - 230
  • [10] Maintenance chemotherapy (MC) in advanced non-small cell Jung cancer (NSCLC): A meta-analysis.
    De Castria, Tiago Biachi
    Castro, Gilberto
    Hoff, Paulo Marcelo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345